Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
In December 2019, a novel coronavirus was isolated from the respiratory epithelium of
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
AM Arvin, K Fink, MA Schmid, A Cathcart, R Spreafico… - Nature, 2020 - nature.com
Antibody-dependent enhancement (ADE) of disease is a general concern for the
development of vaccines and antibody therapies because the mechanisms that underlie …
development of vaccines and antibody therapies because the mechanisms that underlie …
[HTML][HTML] Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Antibodies elicited by infection accumulate somatic mutations in germinal centers that can
increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related …
increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related …
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …
protection of individuals and populations against SARS-CoV-2. Moreover, passively …
[HTML][HTML] Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 …
(SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 …
Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein
The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in more than 28,000,000 infections and 900,000 …
coronavirus 2 (SARS-CoV-2) has resulted in more than 28,000,000 infections and 900,000 …
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
Convalescent plasma is a leading treatment for coronavirus disease 2019 (COVID-19), but
there is a paucity of data identifying its therapeutic efficacy. Among 126 potential …
there is a paucity of data identifying its therapeutic efficacy. Among 126 potential …
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
KH Dinnon III, SR Leist, A Schäfer, CE Edwards… - Nature, 2020 - nature.com
Coronaviruses are prone to transmission to new host species, as recently demonstrated by
the spread to humans of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
the spread to humans of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …